Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.

<h4>Objective</h4>To assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).<h4>Methods</h4>Patients aged 18-50 years with RRMS (Expanded Disability Status Scale sco...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesco Patti, Vincenzo Brescia Morra, Maria Pia Amato, Maria Trojano, Stefano Bastianello, Maria Rosalia Tola, Salvatore Cottone, Andrea Plant, Orietta Picconi, COGIMUS Study Group
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/800e43a06cb94062af19133380974aa3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:800e43a06cb94062af19133380974aa3
record_format	dspace
spelling	oai:doaj.org-article:800e43a06cb94062af19133380974aa32021-11-18T08:57:30ZSubcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.1932-620310.1371/journal.pone.0074111https://doaj.org/article/800e43a06cb94062af19133380974aa32013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24137499/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>To assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).<h4>Methods</h4>Patients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.<h4>Results</h4>Of 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = 108; 22 µg, n = 93) completed 5 years' follow-up. The proportion of patients with cognitive impairment in the study population overall remained stable between baseline (18.0%) and year 5 (22.6%). The proportion of patients with cognitive impairment also remained stable in both treatment groups between baseline and year 5, and between year 3 and year 5. However, a significantly higher proportion of men than women had cognitive impairment at year 5 (26.5% vs 14.4%, p = 0.046). Treatment with the 22 versus 44 µg dose was predictive of cognitive impairment at year 5 (hazard ratio 0.68; 95% confidence interval 0.48-0.97).<h4>Conclusions</h4>This study suggests that sc IFN β-1a dose-dependently stabilizes or delays cognitive impairment over a 5-year period in most patients with mild RRMS. Women seem to be more protected against developing cognitive impairment, which may indicate greater response to therapy or the inherently better prognosis associated with female sex in MS.Francesco PattiVincenzo Brescia MorraMaria Pia AmatoMaria TrojanoStefano BastianelloMaria Rosalia TolaSalvatore CottoneAndrea PlantOrietta PicconiCOGIMUS Study GroupPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 8, p e74111 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Francesco Patti Vincenzo Brescia Morra Maria Pia Amato Maria Trojano Stefano Bastianello Maria Rosalia Tola Salvatore Cottone Andrea Plant Orietta Picconi COGIMUS Study Group Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
description	<h4>Objective</h4>To assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).<h4>Methods</h4>Patients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.<h4>Results</h4>Of 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = 108; 22 µg, n = 93) completed 5 years' follow-up. The proportion of patients with cognitive impairment in the study population overall remained stable between baseline (18.0%) and year 5 (22.6%). The proportion of patients with cognitive impairment also remained stable in both treatment groups between baseline and year 5, and between year 3 and year 5. However, a significantly higher proportion of men than women had cognitive impairment at year 5 (26.5% vs 14.4%, p = 0.046). Treatment with the 22 versus 44 µg dose was predictive of cognitive impairment at year 5 (hazard ratio 0.68; 95% confidence interval 0.48-0.97).<h4>Conclusions</h4>This study suggests that sc IFN β-1a dose-dependently stabilizes or delays cognitive impairment over a 5-year period in most patients with mild RRMS. Women seem to be more protected against developing cognitive impairment, which may indicate greater response to therapy or the inherently better prognosis associated with female sex in MS.
format	article
author	Francesco Patti Vincenzo Brescia Morra Maria Pia Amato Maria Trojano Stefano Bastianello Maria Rosalia Tola Salvatore Cottone Andrea Plant Orietta Picconi COGIMUS Study Group
author_facet	Francesco Patti Vincenzo Brescia Morra Maria Pia Amato Maria Trojano Stefano Bastianello Maria Rosalia Tola Salvatore Cottone Andrea Plant Orietta Picconi COGIMUS Study Group
author_sort	Francesco Patti
title	Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
title_short	Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
title_full	Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
title_fullStr	Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
title_full_unstemmed	Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
title_sort	subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the cogimus study.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/800e43a06cb94062af19133380974aa3
work_keys_str_mv	AT francescopatti subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT vincenzobresciamorra subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT mariapiaamato subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT mariatrojano subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT stefanobastianello subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT mariarosaliatola subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT salvatorecottone subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT andreaplant subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT oriettapicconi subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy AT cogimusstudygroup subcutaneousinterferonb1amayprotectagainstcognitiveimpairmentinpatientswithrelapsingremittingmultiplesclerosis5yearfollowupofthecogimusstudy
_version_	1718421093065162752

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.

Ejemplares similares